Biosimilar Antibodies

Mitumomab is a mouse-derived IgG2b monoclonal antibody with anti-idiotypic properties, designed to mimic the structure of the ganglioside GD3. This antibody is primarily utilized in the study of small-cell lung carcinoma, offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic targets of this aggressive cancer type.

Ocaratuzumab (AME 133v) is an Fc-engineered, humanized IgG1 monoclonal antibody targeting CD20, characterized by a dissociation constant (Kd) of approximately 100 pM. This antibody demonstrates enhanced efficacy in antibody-dependent cell-mediated cytotoxicity (ADCC), making it a potent candidate for research in immune-mediated therapeutic strategies.

Ublituximab, also known as LFB-R603, TG-1101, and TGTX-1101, represents a next-generation, type 1 chimeric monoclonal antibody designed to selectively bind to a unique epitope on the CD20 antigen. This targeting facilitates the induction of cytotoxic effects against CD20-expressing B cells, commonly implicated in various hematological malignancies. Ublituximab's mechanism of action and specificity make it a valuable tool in the research and treatment of cancer.

The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized monoclonal antibody specifically targeting CTSS/Cathepsin S, expressed in Chinese Hamster Ovary (CHO) cells. This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control. This antibody is essential for research focusing on the role of CTSS/Cathepsin S in various biological processes and diseases.

GBR-900 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the TrkA/NTRK1 receptor. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

The Anti-SARS-80R monoclonal antibody (mAb) is a human IgG1 isotype produced in Chinese Hamster Ovary (CHO) cells. This antibody exhibits specific binding to the Spike (S1) protein of the SARS coronavirus, effectively blocking the virus's ability to infect susceptible cells. This mAb serves as a critical tool for research focused on the mechanisms of SARS virus entry and pathogenesis, and is suitable for use in virus neutralization studies and other virological applications.

Depatuxizumab is a brain-penetrant, humanized monoclonal antibody specifically targeting the epidermal growth factor receptor (EGFR). This antibody demonstrates selective inhibition of both mutant EGFRvIII and wild-type EGFR, effectively impeding the growth of xenograft models that express these receptors. Depatuxizumab is primarily utilized in cancer research, offering significant utility in the study of tumor biology and therapeutic antibody development.

Emugrobart is a humanized IgG1κ antibody that specifically targets GDF8 (Growth Differentiation Factor 8). For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control. This antibody is designed for precise specificity and is ideal for research focusing on muscle growth and differentiation pathways.

Riliprubart (SAR445088) is a humanized monoclonal antibody targeting C1s, a critical enzyme in the proximal segment of the classical complement pathway. This antibody selectively binds to activated C1s, effectively preventing its enzymatic activity on substrates C4 and C2. By inhibiting these interactions, Riliprubart impedes the formation of the classical pathway C3 convertase, C4b2a, thus modulating the immune response. This specific inhibition mechanism makes Riliprubart a valuable tool for research into immune regulation and the pathophysiology of diseases mediated by the classical complement system.

Siltuximab is a monoclonal antibody that targets interleukin-6 (IL-6), demonstrating significant antitumor activity. This antibody is utilized in the study of Multicentric Castleman's Disease (MCD) and is also applicable in research related to COVID-19, providing a valuable tool for investigating the role of IL-6 in these disease processes.

Ebrasodebart is a human monoclonal antibody of the IgG4λ subtype that specifically targets TMEM219. For experimental rigor, the recommended isotype control is Human IgG4 (S228P) lambda1. This control is crucial for distinguishing specific from non-specific binding in assays involving Ebrasodebart.

RG-7212 (RO5458640) is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TNFSF12/TWEAK. This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain. The predicted molecular weight of RG-7212 is approximately 146.02 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Imalumab (BAX69) is a recombinant human IgG1 monoclonal antibody specifically designed to target macrophage migration inhibitory factor (MIF). This antibody is utilized primarily in the study of ovarian carcinoma, recurrent malignant ascites, and various cancers, providing a critical tool for researchers investigating the role of MIF in tumor biology and immune response modulation.

Dalnicastobart (LVGN-7409) is a human IgG1κ monoclonal antibody specifically designed to target CD40, also known as TNFRSF5. This antibody is engineered to bind selectively to CD40, a member of the tumor necrosis factor receptor superfamily, playing a crucial role in immune system regulation and the promotion of immune responses. Dalnicastobart is utilized predominantly in research focused on immunological responses and potential therapeutic interventions for autoimmune diseases and cancers.

Batoclimab is a fully humanized IgG1 monoclonal antibody that specifically targets the neonatal Fc receptor (FcRn). This antibody is designed for use in research focused on autoimmune disorders, including myasthenia gravis and thyroid eye disease. Batoclimab's mechanism of action involves modulating the pathway of IgG recycling, potentially altering the autoimmune response. This makes it a valuable tool for studies aimed at understanding and treating conditions mediated by pathogenic autoantibodies.

LY2787106 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Hepcidin, also known as HAMP. This antibody is comprised of a human IgG4SP subtype heavy chain and a human kappa (huκ) light chain, with an estimated molecular weight of 144.2 kDa. For experimental control purposes, the appropriate isotype control is Human IgG4 kappa.

The Anti-HGFA Antibody is a humanized monoclonal antibody specifically targeting hepatocyte growth factor activator (HGFA). Expressed in Chinese hamster ovary (CHO) cells, this antibody is composed of a human IgG1 heavy chain and a human kappa light chain, resulting in a predicted molecular weight of 150 kDa. For isotype control, researchers should use the Human IgG1 kappa, Isotype Control, ensuring accurate experimental comparisons. This antibody is essential for studies involving the regulation and modulation of HGFA, a key enzyme in tissue repair and regeneration processes.

Anzurstobart (CC-95251; BMS-986351) is a fully human monoclonal antibody targeting SIRPα with high affinity. This antibody effectively inhibits the interaction between CD47 and SIRPα, a critical pathway that tumors exploit to evade immune destruction. By blocking this interaction, Anzurstobart enhances the phagocytic activity of macrophages, particularly in co-culture models of diffuse large B-cell lymphoma (DLBCL) when used in conjunction with Rituximab. This antibody is primarily researched for its therapeutic potential in both solid tumors and hematological malignancies, offering significant insights into immune checkpoint blockade strategies.

KY-1044 (Alomfilimab; SAR 445256) is a fully humanized IgG1 monoclonal antibody that selectively targets the inducible costimulatory receptor (ICOS). This antibody is designed to deplete ICOS-high expressing cells through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), facilitated by the engagement of FcγRIIIa receptors. Additionally, KY-1044 serves as a costimulatory molecule for cells expressing lower levels of ICOS, such as CD8+ effector T cells, via FcγR-dependent clustering. This dual functionality allows KY-1044 to modulate the differential expression of ICOS across various T-cell subtypes, thereby enhancing the intratumoral immune contexture and promoting an effective antitumor immune response. KY-1044 is primarily researched for its potential therapeutic applications in oncology, focusing on its ability to manipulate immune responses within the tumor microenvironment.

Fanastomig is a monoclonal antibody designed to target and inhibit both PDCD1 (Programmed cell death protein 1) and LAG3 (Lymphocyte activation gene-3). This dual-targeting approach enhances its potential for modulating immune responses, making it particularly relevant for research in immune checkpoint regulation and cancer immunotherapy.

Eclutatug is a humanized IgG1κ monoclonal antibody specifically targeting CLDN1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Safimestomig is a bispecific IgG4κ antibody designed to target CD47 and CD274. For experimental control purposes, the recommended isotype control is Human IgG4 (S228P) kappa. This control is essential for validating the specificity and ensuring the accuracy of bioassays involving Safimestomig.

Camrelizumab (SHR-1210) is a high-affinity, humanized IgG4-κ monoclonal antibody that targets the PD-1 receptor. This antibody demonstrates a binding affinity of 3 nM for PD-1 and effectively inhibits the PD-1/PD-L1 interaction with an IC50 of 0.70 nM. As an anti-PD-1/PD-L1 therapeutic agent, Camrelizumab is utilized in the investigation of various cancers, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), Hodgkin lymphoma, and advanced hepatocellular carcinoma (HCC), among others. This specificity and potency make it a valuable tool in oncology research, facilitating the exploration of immune checkpoint pathways and their role in immune evasion by tumors.

Daclizumab (Zenapax) is a humanized monoclonal antibody designed to specifically target and block CD25, the α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA). By reversibly binding to CD25, Daclizumab inhibits the interaction between interleukin-2 (IL-2) and its receptor, thereby modulating the immune response. This antibody is primarily utilized in research focused on multiple sclerosis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions in this disease.

Narsoplimab (OMS 721) is a fully human monoclonal antibody of the immunoglobulin gamma 4 (IgG4) subclass, characterized by its high affinity for MASP-2, effectively inhibiting the activation of the lectin pathway. This antibody is pivotal in research focused on hematopoietic stem-cell transplantation and the study of SARS-CoV-2, offering significant insights into therapeutic interventions and immune response mechanisms.

Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that targets programmed cell death protein 1 (PD-1). This antibody is designed for advanced research applications focusing on the modulation of immune checkpoints in oncological studies. Pucotenlimab facilitates the study of PD-1's role in tumor immune evasion and therapy response, providing a crucial tool for cancer research and potential therapeutic strategy development.

Libivirumab (17.1.41) is a human monoclonal antibody targeting the hepatitis B virus (HBV). It exhibits potent neutralizing activity against HBV surface antigen (HBsAg) and HBV e antigen (HBeAg), with half-maximal inhibitory concentrations (IC50) of 35 ng/mL and 130 ng/mL, respectively. This antibody is designed for use in research studies aimed at understanding HBV pathogenesis and for the development of therapeutic strategies against HBV infections.

Belimumab, also known as LymphoStat-B, is a humanized IgG1λ monoclonal antibody designed to target and neutralize B-lymphocyte stimulator (BLyS) protein. By antagonizing the activity of BLyS, Belimumab is utilized in the study of autoimmune disorders and B-cell malignancies. This antibody is particularly relevant for research focused on systemic lupus erythematosus (SLE), providing a valuable tool for understanding and potentially modulating disease mechanisms.

Telikibart is a human monoclonal antibody of the IgG1κ isotype, specifically designed to target the IL4 receptor (IL4R). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is pivotal in studies investigating the role of the IL4R in immune response and inflammatory processes.

Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody specifically targeting PSMA (Prostate-Specific Membrane Antigen). This antibody serves as the antigen-binding component of the antibody-drug conjugate (ADC) molecule, ARX517. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-HIV gp120 Antibody (55-36) is a chimeric mouse monoclonal antibody of the IgG1κ subtype designed specifically to target the HIV gp120 glycoprotein. This antibody serves as a crucial tool in the study of HIV infection mechanisms and the development of therapeutic strategies. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control with this antibody.

Bimekizumab is a humanized monoclonal antibody designed to selectively neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). These cytokines are known to promote osteogenic differentiation in human periosteum-derived cells (hPDCs). By targeting IL-17A and IL-17F, Bimekizumab effectively inhibits the inflammation-driven osteogenic differentiation, making it a valuable tool in research focused on inflammatory processes and bone metabolism.

The Anti-Complement Factor P/Properdin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Complement Factor P, also known as Properdin, a critical component in the complement system that enhances the activation of the alternative pathway. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This product is ideal for use in research applications focused on the study of immune response modulation and complement system mechanisms.

Frexalimab (SAR441344) is a second-generation monoclonal antibody designed to target the CD40 ligand (CD40L). This antibody demonstrates a favorable safety profile and functions by inhibiting the interaction between CD40 and CD40L, thereby modulating the immune response. Frexalimab shows potential in preventing β-cell destruction, suggesting its utility in therapeutic research related to autoimmune diseases such as multiple sclerosis, lupus erythematosus, Sjögren’s syndrome, and type I diabetes.

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody engineered to target CLEC12A on myeloid cells and CD3 on cytotoxic T cells. CLEC12A is recognized as a myeloid differentiation antigen. This antibody facilitates the targeted destruction of both acute myeloid leukemia (AML) progenitor and stem cells. It achieves this through the induction of T cell-mediated cytotoxicity, leading to the proliferative lysis of AML cells. Tepoditamab (MCLA-117) is particularly valuable for research focused on the mechanisms and therapeutic interventions of acute myeloid leukemia.

Sabestomig is a monoclonal antibody targeting PDCD1 (Programmed Cell Death Protein 1) and HAVCR2 (Hepatitis A Virus Cellular Receptor 2), with an isotype composition of IgG1-κ and IgG1-λ2. This antibody is engineered for high specificity and affinity in binding to its targets, making it suitable for use in research studies focused on immune checkpoint pathways and their roles in immunology and oncology.

Zigakibart (BION-1301) is a humanized IgG4-kappa monoclonal antibody targeting TNFSF13, also known as tumor necrosis factor superfamily member 13, APRIL, or CD256. This antibody exhibits anti-inflammatory properties, making it a valuable tool for research into inflammatory processes and potential therapeutic interventions.

Anti-IL-13 Antibody (CNTO 607) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, with an approximate molecular weight of 145 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. Anti-IL-13 Antibody (CNTO 607) is essential for research focused on the role of IL-13 in various biological processes and disease states, including allergic responses and other inflammatory conditions.

FZ-A038 is a humanized monoclonal antibody that specifically targets delta-like ligand 3 (DLL3). This antibody serves as a foundational component for the synthesis of the DLL3-targeted antibody-drug conjugate (ADC), FZ-AD005, offering potential applications in therapeutic development.

Rezorstobart is a human IgG1 κ monoclonal antibody targeting KLRB1. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. It specifically binds to the stem fusion domain in HA2, effectively neutralizing H1, H2, H5, and H9 subtypes of influenza A viruses. This antibody is crucial for studies focused on viral entry mechanisms and the development of broad-spectrum antiviral therapies.

Retavibart is a recombinant human respiratory syncytial virus (RSV) fusion glycoprotein F, designed for use in antiviral research. This product serves as a critical tool in the study of viral entry and fusion mechanisms of RSV. The isotype of Retavibart is Human IgG1 kappa, making it suitable for a variety of experimental setups requiring this specific control.

Secukinumab (AIN457) is a human monoclonal antibody with high affinity for interleukin-17A (IL-17A), representing the first-in-class anti-IL-17 agent. It is utilized in research focused on inflammatory diseases including plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. This specificity to IL-17A makes it a critical tool in the study of immune response mechanisms and therapeutic intervention in these conditions.

Ogalvibart (C-135-LS) is a human monoclonal antibody of the IgG1 subtype, specifically designed to target the SARS-CoV-2 virus. It exhibits high affinity binding to the receptor-binding domain (RBD) of the spike (S) glycoprotein on the virus surface. When used in conjunction with C144LS at a 1:1 ratio, Ogalvibart demonstrates significant preventive efficacy, effectively inhibiting the progression of COVID-19 in a rhesus monkey model. This antibody is pivotal for research focused on the mechanisms of SARS-CoV-2 infection and the development of therapeutic strategies.

Anti-IL-13 (M1295) is a humanized monoclonal antibody specifically targeting interleukin-13 (IL-13). This antibody binds with high affinity to IL-13, a key cytokine involved in inflammatory responses, making it an essential tool for research in immunology and inflammation. Anti-IL-13 (M1295) is suitable for a variety of applications, including flow cytometry, western blotting, and immunohistochemistry, providing valuable insights into the role of IL-13 in disease processes such as asthma and allergies.

Garetatug is a humanized monoclonal antibody designed to target and bind specifically to human Claudin-18 (CLDN18), a tight junction protein. By binding to CLDN18, Garetatug disrupts critical cell signaling pathways, thereby exerting antitumor effects. This antibody is utilized primarily in research focused on the mechanisms of tumor progression and therapeutic intervention.

The Anti-Haptoglobin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Haptoglobin, a key protein involved in hemoglobin binding and iron recovery. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for use in a variety of immunodetection methodologies to study or quantify Haptoglobin levels in biological samples.

Masavibart (ZRC3308-A7) is a monoclonal antibody of the IgG1 subtype, specifically designed to target SARS-CoV-2. This antibody exhibits strong binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Masavibart can be co-administered with ZRC3308-B10 in a 1:1 ratio. This combination has shown potential in the prevention of COVID-19, particularly effective in the initial stages of the disease, prior to the onset of severe symptoms.